vs

Side-by-side financial comparison of Immunovant, Inc. (IMVT) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Red Cat Holdings, Inc. is the larger business by last-quarter revenue ($9.6M vs $8.4M, roughly 1.2× Immunovant, Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -899.0%, a 733.0% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 140.7%). Red Cat Holdings, Inc. produced more free cash flow last quarter ($-24.5M vs $-59.8M).

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

IMVT vs RCAT — Head-to-Head

Bigger by revenue
RCAT
RCAT
1.2× larger
RCAT
$9.6M
$8.4M
IMVT
Growing faster (revenue YoY)
RCAT
RCAT
+847.5% gap
RCAT
988.2%
140.7%
IMVT
Higher net margin
RCAT
RCAT
733.0% more per $
RCAT
-166.0%
-899.0%
IMVT
More free cash flow
RCAT
RCAT
$35.3M more FCF
RCAT
$-24.5M
$-59.8M
IMVT

Income Statement — Q4 FY2024 vs Q3 FY2025

Metric
IMVT
IMVT
RCAT
RCAT
Revenue
$8.4M
$9.6M
Net Profit
$-75.3M
$-16.0M
Gross Margin
6.6%
Operating Margin
-896.2%
-181.7%
Net Margin
-899.0%
-166.0%
Revenue YoY
140.7%
988.2%
Net Profit YoY
-26.7%
-29.0%
EPS (diluted)
$-0.50
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMVT
IMVT
RCAT
RCAT
Q3 25
$9.6M
Q1 25
$1.6M
Q4 24
$0
Q1 24
$8.4M
$5.8M
Q4 23
$8.9M
Q3 23
$3.6M
Q2 23
$4.1M
Q1 23
$3.5M
Net Profit
IMVT
IMVT
RCAT
RCAT
Q3 25
$-16.0M
Q1 25
$-23.1M
Q4 24
$-13.3M
Q1 24
$-75.3M
$-5.5M
Q4 23
$-51.4M
Q3 23
$-58.7M
Q2 23
$-73.9M
Q1 23
$-59.4M
Gross Margin
IMVT
IMVT
RCAT
RCAT
Q3 25
6.6%
Q1 25
-52.2%
Q4 24
Q1 24
18.8%
Q4 23
Q3 23
Q2 23
Q1 23
Operating Margin
IMVT
IMVT
RCAT
RCAT
Q3 25
-181.7%
Q1 25
-765.7%
Q4 24
Q1 24
-896.2%
-76.0%
Q4 23
-576.8%
Q3 23
-1629.6%
Q2 23
-1819.1%
Q1 23
-1736.3%
Net Margin
IMVT
IMVT
RCAT
RCAT
Q3 25
-166.0%
Q1 25
-1418.9%
Q4 24
Q1 24
-899.0%
-93.9%
Q4 23
-575.6%
Q3 23
-1642.3%
Q2 23
-1818.9%
Q1 23
-1707.8%
EPS (diluted)
IMVT
IMVT
RCAT
RCAT
Q3 25
$-0.16
Q1 25
$-0.27
Q4 24
Q1 24
$-0.50
Q4 23
$-0.36
Q3 23
$-0.45
Q2 23
$-0.57
Q1 23
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMVT
IMVT
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$635.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$617.8M
$253.3M
Total Assets
$666.4M
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMVT
IMVT
RCAT
RCAT
Q3 25
Q1 25
Q4 24
Q1 24
$635.4M
Q4 23
$690.9M
Q3 23
$269.9M
Q2 23
$330.0M
Q1 23
$376.5M
Stockholders' Equity
IMVT
IMVT
RCAT
RCAT
Q3 25
$253.3M
Q1 25
$28.9M
Q4 24
$27.0M
Q1 24
$617.8M
$49.6M
Q4 23
$679.3M
Q3 23
$251.8M
Q2 23
$299.9M
Q1 23
$362.5M
Total Assets
IMVT
IMVT
RCAT
RCAT
Q3 25
$286.0M
Q1 25
$59.7M
Q4 24
$51.1M
Q1 24
$666.4M
$55.3M
Q4 23
$711.4M
Q3 23
$292.1M
Q2 23
$351.2M
Q1 23
$405.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMVT
IMVT
RCAT
RCAT
Operating Cash FlowLast quarter
$-59.7M
$-23.9M
Free Cash FlowOCF − Capex
$-59.8M
$-24.5M
FCF MarginFCF / Revenue
-714.4%
-254.2%
Capex IntensityCapex / Revenue
1.8%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-214.6M
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMVT
IMVT
RCAT
RCAT
Q3 25
$-23.9M
Q1 25
$-15.9M
Q4 24
$-10.1M
Q1 24
$-59.7M
$-4.1M
Q4 23
$-47.1M
Q3 23
$-60.1M
Q2 23
$-47.4M
Q1 23
$-55.8M
Free Cash Flow
IMVT
IMVT
RCAT
RCAT
Q3 25
$-24.5M
Q1 25
$-16.2M
Q4 24
$-10.2M
Q1 24
$-59.8M
$-4.2M
Q4 23
$-47.2M
Q3 23
$-60.1M
Q2 23
$-47.4M
Q1 23
$-55.8M
FCF Margin
IMVT
IMVT
RCAT
RCAT
Q3 25
-254.2%
Q1 25
-992.9%
Q4 24
Q1 24
-714.4%
-71.1%
Q4 23
-528.7%
Q3 23
-1682.4%
Q2 23
-1166.4%
Q1 23
-1604.0%
Capex Intensity
IMVT
IMVT
RCAT
RCAT
Q3 25
6.9%
Q1 25
16.8%
Q4 24
Q1 24
1.8%
0.8%
Q4 23
1.5%
Q3 23
1.0%
Q2 23
1.1%
Q1 23
0.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMVT
IMVT

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons